Compound Summary
Compound Information
levodopa
Compound Name: | levodopa |
Compound CID: | 6047 |
Synonyms: | levodopa L-dopa 59-92-7 3,4-dihydroxy-L-phenylalanine 3-Hydroxy-L-tyrosine More... |
Iupac Name: | (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid |
InChI: | InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1 |
InChIKey: | WTDRDQBEARUVNC-LURJTMIESA-N |
Canonical Smiles: | C1=CC(=C(C=C1CC(C(=O)O)N)O)O |
Isomeric Smiles: | C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O |
Molecular Weight: | 197.19 |
Molecular Formula: | C9H11NO4 |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
levodopa
Molecular Weight: | 197.19 |
Molecular Formula: | C9H11NO4 |
Hydrogen Bond Donor Count: | 4 |
Hydrogen Bond Acceptor Count: | 5 |
Rotatable Bond Count: | 3 |
Heavy Atom Count: | 14 |
Complexity: | 209 |
Synonyms
levodopa
| levodopa | levodopa |
|---|---|
levodopa |
L-dopa |
59-92-7 |
3,4-dihydroxy-L-phenylalanine |
3-Hydroxy-L-tyrosine |
Dopar |
Bendopa |
Larodopa |
Levopa |
3-(3,4-Dihydroxyphenyl)-L-alanine |
Brocadopa |
Cidandopa |
Insulamina |
Maipedopa |
Dopaidan |
Dopalina |
Dopasol |
Eldopal |
Eldopar |
Pardopa |
Prodopa |
Syndopa |
3,4-Dihydroxyphenylalanine |
(-)-Dopa |
Dihydroxy-L-phenylalanine |
Helfo-Dopa |
Dopaflex |
Deadopa |
Dopal-fher |
Doparkine |
Dopaston |
Dopastral |
Eldopatec |
Eurodopa |
Doparl |
Doprin |
Veldopa |
L-3,4-Dihydroxyphenylalanine |
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid |
Levedopa |
L-o-Hydroxytyrosine |
Dopa |
Levodopum |
Ledopa |
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine |
L-Tyrosine, 3-hydroxy- |
3,4-Dihydroxyphenyl-L-alanine |
Dopaston SE |
beta-(3,4-Dihydroxyphenyl)-L-alanine |
L-(o-Dihydroxyphenyl)alanine |
L-(-)-Dopa |
L-3-Hydroxytyrosine |
L-beta-(3,4-Dihydroxyphenyl)alanine |
Weldopa |
Parda |
L-Dihydroxyphenylalanine |
L-3-(3,4-Dihydroxyphenyl)alanine |
C9H11NO4 |
Ro 4-6316 |
beta-(3,4-Dihydroxyphenyl)alanine |
(S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid |
alanine, 3-(3,4-dihydroxyphenyl)-, L- |
component of Sinemet |
Dopar (TN) |
CHEBI:15765 |
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine |
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine |
UNII-46627O600J |
Alanine, 3-(3,4-dihydroxyphenyl)-, (-)- |
L(-)-Dopa |
(-)-(3,4-Dihydroxyphenyl)alanine |
MFCD00002598 |
L-3,4-Dihydrophenylalanine |
L-.beta.-(3,4-Dihydroxyphenyl)alanine |
CHEMBL1009 |
.beta.-(3,4-Dihydroxyphenyl)-L-alanine |
L-(3,4-Dihydroxyphenyl)alanine |
CVT-301 |
dihydroxyphenylalanine |
L-Tyrosine, 3-hydroxy-, homopolymer |
NSC118381 |
.beta.-(3,4-Dihydroxyphenyl)alanine |
NSC-118381 |
CAS-59-92-7 |
NCGC00016270-04 |
Biodopa |
Cerepap |
Laradopa |
Sobiodopa |
L-(3,4-Dihydroxyphenyl)-.alpha.-alanine |
46627O600J |
Helfo DOPA |
beta-(3,4-Dihydroxyphenyl)-alpha-alanine |
Atamet |
Levodopum INN-Latin |
BDBM50130192 |
L-O-Dihydroxyphenylalanine |
L Dopa |
65170-01-6 |
CCRIS 3766 |
HSDB 3348 |
WLN: QVYZ1R CQ DQ |
3,4-Dihydroxyphenylalanine (VAN) |
SR-01000075384 |
EINECS 200-445-2 |
NSC 118381 |
Dopastone |
Dopicar |
Inbrija |
Prolopa |
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate |
Prestwick_185 |
Levodopa (Sinemet) |
L-DOPA; Levodopa |
Madopa (Salt/Mix) |
Levodopa USAN:USP:INN:BAN:JAN |
Spectrum_000454 |
Carbidopa EP Impurity A |
Prestwick0_000017 |
Prestwick1_000017 |
Prestwick2_000017 |
Prestwick3_000017 |
Spectrum2_000496 |
Spectrum4_000539 |
Spectrum5_001899 |
Lopac-D-9628 |
Levodopa (JP15/USP) |
DSSTox_CID_3209 |
bmse000322 |
Epitope ID:150927 |
3, 4-Dihydroxyphenylalanine |
Alanine,4-dihydroxyphenyl)- |
DSSTox_RID_76926 |
DSSTox_GSID_23209 |
Lopac0_000454 |
SCHEMBL22655 |
BSPBio_000053 |
BSPBio_002354 |
KBioGR_001177 |
KBioSS_000934 |
L-4-5-Dihydroxyphenylalanine |
MLS000028514 |
BIDD:GT0158 |
DivK1c_000452 |
SPECTRUM2300205 |
Levodopa (JP17/USP/INN) |
SPBio_000391 |
SPBio_001974 |
BPBio1_000059 |
GTPL3639 |
b-(3,4-Dihydroxyphenyl)alanine |
DTXSID9023209 |
WLN: QVYZ1R CQ DQ -L |
3, 4-Dihydroxy-L-phenylalanine |
BDBM60928 |
HMS501G14 |
KBio1_000452 |
KBio2_000934 |
KBio2_003502 |
KBio2_006070 |
Alanine,4-dihydroxyphenyl)-, L- |
L-(3, 4-Dihydroxyphenyl)alanine |
NINDS_000452 |
3-Ethoxy-4-fluorophenylboronicacid |
HMS1568C15 |
HMS1922J14 |
HMS2090O08 |
HMS2093N04 |
HMS2095C15 |
HMS2230B04 |
HMS3261K10 |
HMS3712C15 |
Pharmakon1600-02300205 |
ZINC895199 |
H-Phe{3,4-(OH)2}-OH |
HY-N0304 |
Levodopa;3,4-Dihydroxyphenylalanine |
b-(3,4-Dihydroxyphenyl)-L-alanine |
Inbrija (levodopa inhalation powder) |
Tox21_110338 |
Tox21_500454 |
CCG-39571 |
L-3-(3,4-dihydroxy-phenyl)alanine |
L-3-(3,4-dihydroxyphenyl)-Alanine |
NSC759573 |
PDSP1_001541 |
PDSP2_001525 |
s1726 |
SBB017533 |
Alanine, 3-(3,4-dihydroxyphenyl)- |
Alanine,4-dihydroxyphenyl)-, (-)- |
AKOS010396267 |
b-(3,4-Dihydroxyphenyl)-a-L-alanine |
L-b-(3,4-Dihydroxyphenyl)-a-alanine |
.beta.-(3, 4-Dihydroxyphenyl)alanine |
AC-8432 |
AM82124 |
CS-1945 |
DB01235 |
LP00454 |
MCULE-4743781842 |
NSC-759573 |
SDCCGMLS-0066924.P001 |
SDCCGSBI-0050439.P004 |
VA11170 |
IDI1_000452 |
NCGC00015384-01 |
NCGC00016270-01 |
NCGC00016270-06 |
NCGC00016270-07 |
NCGC00016270-09 |
NCGC00016270-10 |
NCGC00016270-22 |
NCGC00093869-04 |
NCGC00261139-01 |
AS-13287 |
BP-12850 |
H813 |
SMR000058312 |
ST086623 |
SBI-0050439.P003 |
AB0013279 |
L-(3, 4-Dihydroxyphenyl)-.alpha.-alanine |
D0600 |
D9628 |
EU-0100454 |
N1648 |
59L927 |
Alanine, 3-(3, 4-dihydroxyphenyl)-, (-)- |
C00355 |
D 9628 |
D00059 |
D70595 |
J10404 |
V-1512 |
13173-EP2269989A1 |
13173-EP2277876A1 |
13173-EP2277882A1 |
13173-EP2281559A1 |
13173-EP2281815A1 |
13173-EP2292614A1 |
13173-EP2295412A1 |
13173-EP2295413A1 |
13173-EP2295439A1 |
13173-EP2298731A1 |
13173-EP2301933A1 |
13173-EP2301934A1 |
13173-EP2305633A1 |
13173-EP2305640A2 |
13173-EP2308867A2 |
13173-EP2308870A2 |
13173-EP2311827A1 |
13173-EP2311837A1 |
13173-EP2314571A2 |
13173-EP2316470A2 |
13173-EP2316834A1 |
21660-EP2272832A1 |
21660-EP2275420A1 |
21660-EP2281559A1 |
21660-EP2301934A1 |
21660-EP2314571A2 |
21920-EP2295410A1 |
21920-EP2301939A1 |
21920-EP2314571A2 |
3,4-Dihydroxy-L-phenylalanine, >=98% (TLC) |
AB00052418-06 |
AB00052418-07 |
AB00052418_08 |
AB00052418_09 |
A832543 |
Q300989 |
Q-201294 |
SR-01000075384-1 |
SR-01000075384-4 |
SR-01000075384-6 |
SR-01000075384-7 |
(S)-2-Amino-3-(3,4-dihydroxy-phenyl)-propionic acid |
F0347-4695 |
Levodopa, British Pharmacopoeia (BP) Reference Standard |
Levodopa, European Pharmacopoeia (EP) Reference Standard |
Z1762772338 |
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acidL-dopa |
UNII-QI9C343R60 component WTDRDQBEARUVNC-LURJTMIESA-N |
1E83F927-C221-46AA-B90A-81B33C5F3868 |
3,4-Dihydroxy-L-phenylalanine, Vetec(TM) reagent grade, 98% |
Levodopa, United States Pharmacopeia (USP) Reference Standard |
3,4-Dihydroxy-L-phenylalanine, certified reference material, TraceCERT(R) |
Levodopa, Pharmaceutical Secondary Standard; Certified Reference Material |
122769-74-8 |
L-Methyldopa ; (2S)-2-Amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; 3-(3,4-Dihydroxyphenyl)-?-methyl-L-alanine; 3-Hydroxy-a-methyl-L-tyrosine |
Experimental Data
levodopa
| Species | Dosage | Unit | CG Lifespan(AVG/MED days) | TG Lifespan(AVG/MED days) | Lifespan Change(AVG/MED%) | CG Lifespan(MAX days) | TG Lifespan(MAX days) | Lifespan Change(MAX%) | Significant | Strain | Gender | PubMed | Active Label |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33 | umol/L | 8 | NS | N2 | 24134630 | Inactive | ||||||
| Mus musculus | 2 | mg | 450 | 493 | 9.56 | Unclear | 7390164 |
Experimental Data Visualization
levodopa
Statistics Data
levodopa
| Species | Lifespan Change(AVG/MED%) | Lifespan Change(MAX%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | 8 | 1 | 1 | |
| Mus musculus | 9.56 | 1 | 1 |
Statistics Data Visualization
levodopa
